Latest news with #FALCON
Time of India
02-07-2025
- Entertainment
- Time of India
Mecha Break Twitch drops guide: How to unlock all rewards?
Mecha Break is a high-octane mecha combat game. It has recently rolled out some limited-time Twitch drops, offering players a chance to snag some exclusive in-game items by watching streams. Tired of too many ads? go ad free now With the mix of varied character cosmetics and some mecha customizations available for players, here is all you need to know to claim them before time runs out. Do not miss this chance. How to unlock Mecha Break rewards ? To get the drops is a very straightforward process. So, forget about complex challenges and just watch some qualifying Mecha Break streams available on Twitch. The viewing time will passively accumulate to some specific rewards. Streams must remain under Twitch's Mecha Break category for your time to count. Quite crucially, you must even manually claim all the rewards in the Twitch inventory when you hit the required watch time. To leave them unclaimed means you will lose them forever. The entire event, including the claims, would sharply end on July 31, 2025, at exactly 1:00 pm PDT. Note: The event period begins July 1, 2025, at 9:00 pm and ends July 29, 2025, at 9:00 pm. But the rewards can be claimed up to July 31, 2025, 1:00 pm. Current Season 0 drops will feature 6 tiers of pilot cosmetics. Begin with Arm Accessory: Tactical Watch. To do so, you need to watch the stream for only 15 minutes. Ensure to keep the stream rolling for 30 minutes, and you will earn a Wireless Headset 2 ear accessory. If you dedicate an hour, you will end up with an Airstream Divider headpiece. 2.5 hours would unlock sleek Cyber Visor eyewear. Cybernetic Tail waist accessory, the ultimate pilot gear, requires a 3-hour watch session. Remember that all these rewards are available if you watch any of the eligible Mecha Break streamers till July 29, 2025. Weekly drop rewards for dedicated players Beyond all standard haul, Mecha Break is also running some special weekend drops, all throughout July. They will offer some unique mech insignias and skins. For it, you must tune in to some specific and pre-selected streamers on the designated weekend. Tired of too many ads? go ad free now How to Get Free Exclusive Skin & All rewards in Mecha BREAK (Twitch Drops July) Every week will focus on different Striker mech designs. Week 1 (July 5-6) will feature Striker Design Moonwell for ALYSNES, PANTHER, and WELKIN. Watch stream for 45 minutes, 2 hours, and 1.5 hours, respectively, for each to claim the reward. Week 2 (July 12-13) will cover FALCON, LUMINAE, and SKYRAIDER. Watch stream for 45 minutes, 2 hours, and 1.5 hours, respectively, for each to claim the reward. Week 3 (July 19-20) will bring PINAKA, STEGO, and TRICERA. Watch stream for 2 hours, 1.5 hours, and 45 minutes, respectively, for each to claim the reward. The final week (July 26-27) has AQUILA and NARUKAMI. Watch the stream for 45 minutes and 1.5 hours, respectively, for each to claim the reward. Each of these weeks even offers Shoutcaster insignia. The watch times for specials will range between 20 minutes and 2 hours. Week 4 also features Striker Design Moonwell, which requires 2 hours of watching a stream to claim this reward. All exclusive designs will only be available during specific 2-day windows. To miss that weekend would mean you miss particular mech skins. Like general drops, you must ensure to claim them within Twitch inventory immediately as you earn them. The same July 31, 2025, deadline applies to claim all your earned drops, regular or special. Especially, if you are a serious collector, you must mark these weekends on your calendar. How to claim Mecha Break Twitch rewards? Before anything else, ensure to link the Mecha Break account to the Twitch account. Do it through the official Twitch Drops page or just in the game settings. As it's linked, start finding streams that are tagged under Mecha Break, with the drops enabled. For special weekly drops, make sure you are watching officially designated streamers, in specific event times—weekends that are stated above. The watch progress will be tracked automatically and will be shown on Twitch. When you hit the required watch time for a particular reward, a notification will appear on Twitch. Once it does, go to the Twitch Drops inventory directly. It can be accessed through the profile menu. There, find the Mecha Break reward and just click claim. Once you do, launch the Mecha Break game. Your rewards will appear there within the in-game mailbox. If they are not showing immediately, try to restart the game. Also, do not forget that all claimed items will be permanently added to your account. So, claim them all.
Yahoo
23-06-2025
- Business
- Yahoo
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that data from the completed Phase 1 study of TERN-601, a novel once-daily oral GLP-1R agonist, will be highlighted at the American Diabetes Association (ADA) 85th Scientific Sessions, taking place June 20-23, 2025, in Chicago, IL. 'We are thrilled to be selected for an oral presentation at ADA to highlight additional data from the 28-day Phase 1 study of TERN-601 demonstrating its differentiated profile among oral GLP1-R agonists,' said Amy Burroughs, chief executive officer of Terns. 'In addition, we are pleased to share the recent completion of enrollment for our Phase 2 FALCON trial where the key objectives of the trial are to demonstrate TERN-601's competitive weight loss at 12-weeks, a class leading safety and tolerability profile, and the simplest dose titration amongst GLP-1R agonist therapies.' Topline data from the Phase 1 clinical study being presented at ADA were reported in September 2024 and provided the recommended doses taken forward in the ongoing Phase 2 FALCON study, which recently completed enrollment, with topline data expected in the fourth quarter of 2025. Key highlights from the ADA presentation include: Efficacy Statistically significant and dose-dependent weight loss up to 5.5% over 28 days with QD dosing Dose related increase in weight loss with 67% of patients losing 5% or more body weight at top dose Unique pharmaceutical properties result in flat PK curve allowing 24hr target coverage with QD dosing and effective half-life of 9-10 hours Higher gut vs. plasma exposures and low free fraction drives meaningful weight loss without sacrificing tolerability Safety Well-tolerated despite rapid dose titration every three days No treatment related interruptions, reductions, discontinuations at any dose >95% of GI AEs were mild despite rapid titration No meaningful changes in liver enzymes, vital signs or ECGs Tolerability and ease of use Simplest dose titration amongst GLP1-RA therapies Dosing with or without food Can be administered with PPIs, H2RA and/or antacids The presentations and viewing detail are listed below: Presentation Title: Effect of Oral Small Molecule GLP-1 Receptor Agonist TERN-601 in Healthy Participants with Obesity or Overweight – A First-in-Human Study Abstract Number: 307-OR Presentation Date and Time: Monday, June 23, 2025; 2:30-2:45 PM CT Session Name: Early Phase, Post Hoc, and Subgroup Analyses from Clinical Trials with lncretin-Based Therapies-Take 2 Presenter: Cara H. Nelson, Terns Pharmaceuticals, Foster City, CA, USA Presentation Title: No Effect of Food or Proton Pump Inhibitor on the Pharmacokinetics of TERN-601, an Oral Small Molecule GLP-1 Receptor Agonist Abstract Number: 767-P Presentation Date and Time: Sunday Jun 22, 2025; 12:30 PM - 1 :30 PM CT Session Name: Clinical Therapeutics-lncretin-Based Therapies Presenter: Cara H. Nelson, Terns Pharmaceuticals, Foster City, CA, USA About the TERN-601 Phase 1 Trial The Phase 1 trial was a randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) trial to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TERN-601 in healthy adults with obesity or overweight. The trial consisted of two parts. Part 1 (SAD) was a single ascending dose study that evaluated five TERN-601 dose levels in healthy participants with a Body Mass Index (BMI) of ≥ 25 kg/m2 and < 40 kg/m2. The starting TERN-601 dose was 30 mg, with subsequent dose levels based on review of emerging safety and PK data from prior cohorts. In Part 2 (MAD) of the trial, obese and overweight healthy adults were enrolled in cohorts that included titration of TERN-601 administered for 28 days at doses selected based on data from Part 1 (SAD). Part 2 included healthy participants with a BMI of ≥ 27 kg/m2 to < 40 kg/m2. The primary endpoint of the trial was to evaluate safety and tolerability of TERN-601 administered once-daily for 28 days. Secondary endpoints included PK, efficacy as measured by body weight loss following 28 days of treatment with TERN-601, and other exploratory markers. About FALCON Phase 2 Trial FALCON is an ongoing U.S.-based, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of TERN-601, with once-daily dosing with or without food in adults with obesity or who are overweight, without diabetes (BMI ranges from ≥30 to <50 kg/m2 or ≥27 to <30 kg/m2 with at least one weight-related comorbidity). Patients are randomized to one of four active cohorts (n=30 per cohort): 250 mg, 500 mg, 500 mg slow titration, 750 mg or placebo. The primary endpoint is percent change from baseline in body weight compared to placebo over 12 weeks and secondary endpoints include safety, tolerability and proportion of patients achieving 5% weight loss or greater. About Terns Pharmaceuticals Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about the Company within the meaning of the federal securities laws. Forward-looking statements include statements related to or in connection with the novelty and growth of the Company's intellectual property portfolio; expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners, including with respect to the FALCON trial; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company's small-molecule product candidates; the potential for the mechanisms of action of the Company's product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company's product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company's clinical trials; the potential differentiation of the Company's small-molecule product candidates compared to similar or competitive products or product candidates; the Company's clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company's expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company's plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; and the Company's expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company's strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'believe, 'develop', 'expect', and 'objective' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company's current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Contacts for Terns InvestorsKaytee Bock Zafereoinvestors@ MediaJenna UrbanCG Lifemedia@
Channel Post MEA
13-06-2025
- Business
- Channel Post MEA
Commvault Introduces New Post-Quantum Cryptography Capabilities
Commvault has announced enhancements to its post-quantum cryptography (PQC) capabilities. These advancements are designed to help customers protect their highly sensitive, long-term data from a new generation of imminent but unknown cyber threats, creating an additional layer of support, when needed. Quantum computing uses quantum mechanics to process data and solve complex problems that could take decades with classical computers. However, these advancements bring unprecedented security challenges, along with the potential for threat actors to use quantum computing to decipher and unlock traditional encryption methods. According to the Information Systems Audit and Control Association's (ISACA) Quantum Computing Pulse Poll, 63% of technology and cybersecurity professionals say quantum will increase or shift cybersecurity risks and 50% believe it will present regulatory and compliance challenges. Now is the time to prepare and take action. Commvault has provided support for quantum-resistant encryption standards, like CRYSTALS-Kyber, CRYSTALS-Dilithium, SPHINCS+, and FALCON, as recommended by the National Institute of Standards and Technology (NIST) since August 2024. It was then that Commvault introduced a cryptographic agility (crypto-agility) framework, enabling its customers, via the Commvault Cloud platform, to address rapidly evolving threats without overhauling their systems. With today's announcement, Commvault has built on that framework by adding support for Hamming Quasi-Cyclic (HQC), a new error correcting code-based algorithm designed to defend against threats like 'harvest now, decrypt later' where adversaries are intercepting encrypted network traffic and storing it for a later time when quantum computers are powerful enough to decrypt it. 'The quantum threat isn't theoretical,' said Bill O'Connell, Chief Security Officer at Commvault. 'We were among the first cyber resilience vendors to address post-quantum computing, and by integrating new algorithms like HQC and advancing our crypto-agility framework, we are providing our customers with the tools to navigate this complex landscape with confidence. Our goal is simple and clear: as quantum computing threats emerge, we intend to help our customers keep their data protected.' For industries where long-term data storage is required, like finance and healthcare, Commvault's expanded post-quantum cryptography capabilities provide access to a variety of safeguards that can help fortify network tunnels against quantum-based attacks. With Commvault's Risk Analysis capabilities, customers can discover and classify data to determine where these cryptographic capabilities may be helpful. In addition, Commvault's capabilities are simple to implement, often using a checkbox configuration, making it easy for customers to utilize when needed. The evolving quantum landscape – the need for speed As investments pour into the quantum field, the time to address emerging threats is shrinking. This makes proactive adoption of post-quantum cryptography critical. 'Quantum readiness has become a business imperative, particularly for industries which handle data that remains sensitive for decades. The time when currently encrypted data can be decrypted using quantum technology is closer than many people think,' said Phil Goodwin, Research VP, IDC. 'Commvault's early adoption of quantum-resistant cryptography and commitment to crypto-agility positions it at the forefront among data protection software vendors in proactively addressing quantum threats. Organizations with sensitive, long-term data need to prepare now for a quantum world.' 'Commvault has been an invaluable partner in our journey to enhance cyber resilience. Their leadership in adopting post-quantum cryptography, combined with their crypto-agility framework, is exactly what we need to meet stringent government security mandates and protect highly sensitive information from emerging quantum threats,' said Jeff Day, Deputy Chief Information Security Officer, Nevada Department of Transportation. 'Safeguarding sensitive data is paramount, and the long-term threat of quantum decryption is a significant concern. Commvault's rapid integration of NIST's quantum-resistant standards, particularly HQC, gives us great confidence that our critical information is protected now and well into the future,' said Peter Hands, Chief Information Security Officer, British Medical Association. 'Their commitment to crypto-agility is important for healthcare organizations like ours.' Availability Commvault's post-quantum cryptography capabilities, including support for NIST's HQC algorithm, are immediately available to all Commvault Cloud customers running software version CPR 2024 (11.36) and later, enabling seamless adoption of quantum-resistant protection.
Yahoo
09-06-2025
- Business
- Yahoo
Commvault Unveils New Post-Quantum Cryptography Capabilities to Help Customers Protect Data from a New Generation of Security Threats
Expanded support for new encryption standards empowers customers to proactively safeguard long-term sensitive data against 'harvest now, decrypt later' quantum threats TINTON FALLS, N.J., June 9, 2025 /PRNewswire/ -- At a time when quantum computing is rapidly emerging as an entirely new security challenge for organizations and governments around the world, Commvault, a leading provider of cyber resilience and data protection solutions for the hybrid cloud and one of the first cyber resilience vendors to support post-quantum cryptography (PQC), today announced enhancements to its PQC capabilities. These advancements are designed to help customers protect their highly sensitive, long-term data from a new generation of imminent but unknown cyber threats, creating an additional layer of support, when needed. Quantum computing uses quantum mechanics to process data and solve complex problems that could take decades with classical computers. However, these advancements bring unprecedented security challenges, along with the potential for threat actors to use quantum computing to decipher and unlock traditional encryption methods. According to the Information Systems Audit and Control Association's (ISACA) Quantum Computing Pulse Poll, 63% of technology and cybersecurity professionals say quantum will increase or shift cybersecurity risks and 50% believe it will present regulatory and compliance challenges1. Now is the time to prepare and take action. Commvault has provided support for quantum-resistant encryption standards, like CRYSTALS-Kyber, CRYSTALS-Dilithium, SPHINCS+, and FALCON, as recommended by the National Institute of Standards and Technology (NIST) since August 2024. It was then that Commvault introduced a cryptographic agility (crypto-agility) framework, enabling its customers, via the Commvault Cloud platform, to address rapidly evolving threats without overhauling their systems. With today's announcement, Commvault has built on that framework by adding support for Hamming Quasi-Cyclic (HQC), a new error correcting code-based algorithm designed to defend against threats like 'harvest now, decrypt later' where adversaries are intercepting encrypted network traffic and storing it for a later time when quantum computers are powerful enough to decrypt it. "The quantum threat isn't theoretical," said Bill O'Connell, Chief Security Officer at Commvault. "We were among the first cyber resilience vendors to address post-quantum computing, and by integrating new algorithms like HQC and advancing our crypto-agility framework, we are providing our customers with the tools to navigate this complex landscape with confidence. Our goal is simple and clear: as quantum computing threats emerge, we intend to help our customers keep their data protected." For industries where long-term data storage is required, like finance and healthcare, Commvault's expanded post-quantum cryptography capabilities provide access to a variety of safeguards that can help fortify network tunnels against quantum-based attacks. With Commvault's Risk Analysis capabilities, customers can discover and classify data to determine where these cryptographic capabilities may be helpful. In addition, Commvault's capabilities are simple to implement, often using a checkbox configuration, making it easy for customers to utilize when needed. The evolving quantum landscape – the need for speedAs investments pour into the quantum field, the time to address emerging threats is shrinking. This makes proactive adoption of post-quantum cryptography critical. "Quantum readiness has become a business imperative, particularly for industries which handle data that remains sensitive for decades. The time when currently encrypted data can be decrypted using quantum technology is closer than many people think," said Phil Goodwin, Research VP, IDC. "Commvault's early adoption of quantum-resistant cryptography and commitment to crypto-agility positions it at the forefront among data protection software vendors in proactively addressing quantum threats. Organizations with sensitive, long-term data need to prepare now for a quantum world." "Commvault has been an invaluable partner in our journey to enhance cyber resilience. Their leadership in adopting post-quantum cryptography, combined with their crypto-agility framework, is exactly what we need to meet stringent government security mandates and protect highly sensitive information from emerging quantum threats," said Jeff Day, Deputy Chief Information Security Officer, Nevada Department of Transportation. "Safeguarding sensitive data is paramount, and the long-term threat of quantum decryption is a significant concern. Commvault's rapid integration of NIST's quantum-resistant standards, particularly HQC, gives us great confidence that our critical information is protected now and well into the future," said Peter Hands, Chief Information Security Officer, British Medical Association. "Their commitment to crypto-agility is important for healthcare organizations like ours." Availability Commvault's post-quantum cryptography capabilities, including support for NIST's HQC algorithm, are immediately available to all Commvault Cloud customers running software version CPR 2024 (11.36) and later, enabling seamless adoption of quantum-resistant protection. To learn more about Commvault's quantum-resistant encryption solutions and how to future-proof your data security strategy, read today's blog, watch our executive videos here and here, and check out the executive brief. About CommvaultCommvault (NASDAQ: CVLT) is the gold standard in cyber resilience, helping more than 100,000 organizations keep data safe and businesses resilient and moving forward. Today, Commvault offers the only cyber resilience platform that combines the best data security and rapid recovery at enterprise scale across any workload, anywhere—at the lowest TCO. 1 ISAC. (2025, April 28). Despite Rising Concerns, 95% of Organizations Lack a Quantum Computing Roadmap, ISACA Finds [press release]. View original content to download multimedia: SOURCE COMMVAULT Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
08-05-2025
- Business
- Yahoo
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2025, and provided corporate updates. 'Terns had a strong start to 2025, marked by continued excellent execution on our two lead clinical programs. The dose escalation portion of the TERN-701 Phase 1 study for CML was completed in less than a year, and we are thrilled to report that we have initiated enrollment in the dose expansion portion of the study,' stated Amy Burroughs, chief executive officer of Terns. 'The rapid enrollment in our Phase 2 FALCON trial of TERN-601 in obesity highlights strong interest from patients and clinical investigators in the differentiated profile of this oral small molecule GLP1-RA. We remain on track to deliver meaningful data from both these studies in the second half of this year and have a cash runway that extends into 2028.' 'TERN-701 showed highly encouraging safety with no dose limiting toxicities in dose escalation up to the maximum dose of 500 mg, linear pharmacokinetics with once daily dosing, and compelling molecular responses in patients with high CML disease burden who had responded poorly to multiple prior therapies including asciminib,' said Emil Kuriakose MD, chief medical officer of Terns. 'The favorable safety profile and dose-related increase in molecular responses with TERN-701 allowed us to select doses at the top end of the dose range to take forward to dose expansion.' Recent Clinical Pipeline Developments and Anticipated Milestones TERN-701: Oral, small-molecule next-generation allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) In April 2025, Terns enrolled the first patient in the dose expansion portion of the Phase 1 CARDINAL study of TERN-701 for CML. Patients will be randomized to one of two dose cohorts (320 mg or 500 mg QD) with up to 40 patients per arm. Doses were selected based on the totality of safety, efficacy, and PK/PD data from dose escalation Terns plans to report additional safety and efficacy data from the dose escalation and expansion portions of the study in 4Q 2025, when the study has sufficient patient enrollment and duration of follow-up to meaningfully assess 6-month major molecular response rates (regulatory approval endpoint) and inform the path to a pivotal trial In December 2024, Terns announced interim data from the TERN-701 dose escalation portion of the study, showing: Starting at the lowest dose, compelling molecular responses in heavily pre-treated CML patients with high baseline BCR-ABL transcript levels Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations or dose reductions at any dose TERN-601: Oral, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity Key objectives of the FALCON Phase 2 trial are to demonstrate competitive weight loss at 12-weeks, a class-leading safety/tolerability profile, and the simplest dose titration amongst GLP1-RA therapies The FALCON Phase 2 trial is ongoing with top-line 12-week data expected in 4Q 2025 U.S.-based, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of TERN-601 Once-daily dosing with or without food in adults with obesity or who are overweight, without diabetes (BMI ranges from ≥30 to <50 kg/m2 or ≥27 to <30 kg/m2 with at least one weight-related comorbidity) Patients randomized to one of four active cohorts (n=30 per cohort): 250 mg, 500 mg, 500 mg slow titration, 750 mg or placebo Primary endpoint is percent change from baseline in body weight compared to placebo over 12 weeks Secondary endpoints include safety, tolerability and proportion of patients achieving 5% weight loss or greater Doses and titration schema for the Phase 2 were selected based on positive results from the Phase 1 study, announced in September 2024, which demonstrated weight loss over 28-days up to 5.5% and favorable safety and tolerability despite rapid dose titration every three days Pipeline and Partnering Programs TERN-800 Series: Oral, small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist Terns is prioritizing its discovery efforts on nominating a GIPR antagonist development candidate based on in-house discoveries and growing scientific rationale supporting the potential of GLP-1 agonist/GIPR antagonist combinations for obesity TERN-501: Oral, thyroid hormone receptor-beta (THR-β) agonist Based on non-clinical studies, THR-β is a complementary mechanism to GLP-1, potentially providing broader metabolic and liver benefits in addition to increased weight loss Corporate Updates Members of Terns' senior leadership team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference in New York City, New York being held June 3rd – June 5th, 2025 Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida being held June 9th – June 11th, 2025 Webcasts of these events can be accessed at the Terns website under the 'Events & Presentations' tab on the 'Investors' section of the Company's website on the day of the event: First Quarter 2025 Financial Results Cash Position: As of March 31, 2025, cash, cash equivalents and marketable securities were $334.3 million, as compared with $358.2 million as of December 31, 2024. Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2028. Research and Development (R&D) Expenses: R&D expenses were $18.7 million for the quarter ended March 31, 2025, as compared with $18.6 million for the quarter ended March 31, 2024. General and Administrative (G&A) Expenses: G&A expenses were $8.7 million for the quarter ended March 31, 2025, as compared with $6.9 million for the quarter ended March 31, 2024. Net Loss: Net loss was $23.9 million for the quarter ended March 31, 2025, as compared with $22.4 million for the quarter ended March 31, 2024. Financial Tables Terns Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited; in thousands except share and per share amounts) Three Months Ended March 31, 2025 2024 Operating expenses: Research and development $ 18,720 $ 18,587 General and administrative 8,707 6,859 Total operating expenses 27,427 25,446 Loss from operations (27,427 ) (25,446 ) Interest income 3,643 3,182 Other expense, net (36 ) (12 ) Loss before income taxes (23,820 ) (22,276 ) Income tax expense (88 ) (97 ) Net loss $ (23,908 ) $ (22,373 ) Net loss per share, basic and diluted $ (0.26 ) $ (0.30 ) Weighted average common stock outstanding, basic and diluted 91,473,948 74,399,378 Terns Pharmaceuticals, Inc. Selected Balance Sheet Data (Unaudited; in thousands) March 31, 2025 December 31, 2024 Cash, cash equivalents and marketable securities $ 334,264 $ 358,164 Total assets 339,315 363,929 Total liabilities 13,272 18,059 Total stockholders' equity 326,043 345,870 About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains multiple clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners, including with respect to CARDINAL and FALCON trials, as well as enabling and human studies of the TERN –800 Series and TERN-501; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company's small-molecule product candidates; the potential for the mechanisms of action of the Company's product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company's product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company's clinical trials; the Company's clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company's expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company's plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the potential commercialization of the Company's product candidates; the Company's plans and expectations around the addition of key personnel; and the Company's expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company's strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'design,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'positioned,' 'potential,' 'predict,' 'seek,' 'should,' 'target,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company's current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason. Contacts for Terns InvestorsKaytee Bock Zafereoinvestors@ MediaJenna UrbanCG Life media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
